Skip to main navigation Skip to search Skip to main content

A detailed histologic and molecular assessment of the diffuse sclerosing variant of papillary thyroid carcinoma

  • Angela Chou*
  • , Min Ru Qiu
  • , Henry Crayton
  • , Bin Wang
  • , Mahsa S. Ahadi
  • , John Turchini
  • , Adele Clarkson
  • , Loretta Sioson
  • , Amy Sheen
  • , Nisha Singh
  • , Roderick J. Clifton-Bligh
  • , Bruce G. Robinson
  • , Matti L. Gild
  • , Venessa Tsang
  • , David Leong
  • , Stanley B. Sidhu
  • , Mark Sywak
  • , Leigh Delbridge
  • , Ahmad Aniss
  • , Dale Wright
  • Nicole Graf, Amit Kumar, Vivek Rathi, Paul Benitez-Aguirre, Anthony R. Glover, Anthony J. Gill
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Diffuse sclerosing variant papillary thyroid carcinoma (DS-PTC) is characterized clinically by a predilection for children and young adults, bulky neck nodes, and pulmonary metastases. Previous studies have suggested infrequent BRAFV600E mutation but common RET gene rearrangements. Using strict criteria, we studied 43 DS-PTCs (1.9% of unselected PTCs in our unit). Seventy-nine percent harbored pathogenic gene rearrangements involving RET, NTRK3, NTRK1, ALK, or BRAF; with the remainder driven by BRAFV600E mutations. All 10 pediatric cases were all gene rearranged (P =.02). Compared with BRAFV600E-mutated tumors, gene rearrangement was characterized by psammoma bodies involving the entire lobe (P =.038), follicular predominant or mixed follicular architecture (P =.003), pulmonary metastases (24% vs none, P =.04), and absent classical, so-called “BRAF-like” atypia (P =.014). There was no correlation between the presence of gene rearrangement and recurrence-free survival. Features associated with persistent/recurrent disease included pediatric population (P =.030), gene-rearranged tumors (P =.020), microscopic extrathyroidal extension (P =.009), metastases at presentation (P =.007), and stage II disease (P =.015). We conclude that DS-PTC represents 1.9% of papillary thyroid carcinomas and that actionable gene rearrangements are extremely common in DS-PTC. DS-PTC can be divided into 2 distinct molecular subtypes and all BRAFV600E-negative tumors (1.5% of papillary thyroid carcinomas) are driven by potentially actionable oncogenic fusions.

Original languageEnglish
Article number100329
Pages (from-to)1-10
Number of pages10
JournalModern Pathology
Volume36
Issue number12
DOIs
Publication statusPublished - Dec 2023

Keywords

  • ALK
  • BRAF
  • diffuse sclerosing
  • gene fusions
  • NTRK
  • papillary thyroid carcinoma
  • RET

Fingerprint

Dive into the research topics of 'A detailed histologic and molecular assessment of the diffuse sclerosing variant of papillary thyroid carcinoma'. Together they form a unique fingerprint.

Cite this